<DOC>
	<DOCNO>NCT03083821</DOCNO>
	<brief_summary>A Pharmacokinetics study Baraclude real world clinical setting Japan .</brief_summary>
	<brief_title>A Study Provide Better Understanding Baraclude 's Pharmacokinetic Properties Real World Clinical Setting</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com . Participants chronic hepatitis B ( CHB ) ( exclude participant superinfection ) confirm CHB . Participants treat 0.5 mg daily Baraclude minimum 10 consecutive day prior study enrollment . Body mass index ( BMI ) 18.5 30 kg/m2 ( BMI = body weight [ kg ] /height [ ] 2 ) Current recent ( within 3 month Baraclude administration ) gastrointestinal disease could impact upon absorption study drug . Any gastrointestinal surgery could impact upon absorption study drug . Donation blood blood bank clinical study ( except screen visit ) within 4 week study drug administration ( within 2 week plasma ) . Other protocol define inclusion/exclusion criterion could apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>